FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2584244377> ?p ?o ?g. }

• W2584244377 abstract "Abstract This report updates a retrospective study from SFGM-TC registry concerning 738 patients who underwent RIC HSCT for hematological malignancies [280 F, 458 M, median age: 51 years (1–72)] between 1997 and 2004. The diagnosis were 173 AML, 40 ALL, 68 MDS, 152 NHL, 36 HD, 45 CLL, 70 CML, 154 MM; 332 patients have been previously transplanted. At time of conditioning, 261 patients were in CR, 224 in PR and 253 in progressive disease (PD). Peripheral blood stem cells (PBSC) were used in 574 patients and bone marrow in 164 patients from 655 HLA related donors and 83 unrelated donors. As conditioning, 152 patients received fludarabine and TBI (2 grays), 300 patients fludarabine, busulfan and anti-thymocyte globulins (FBS) (ATG 1d: 57, 2 d: 84, 3 d: 58, 4 d: 18, 5 d: 83) and 286 patients an other regimen. As GVHD prophylaxis, 722 patients received a cyclosporine A (CsA) based regimen. After transplant, 252 patients (35%) in the global population developed an acute GVHD ≥ grade II (grades III and IV: 116) and 208 patients (37%) in the PBSCT population (grades III and IV: 100). A chronic GVHD was present in 258 patients (38%) in the global population (115 limited and 143 extensive) and 221 patients (42%) in the PBSCT population (95 limited and 126 extensive). With a median follow-up of 27 months, the 3-year probability of overall survival (OS) and event-free survival (EFS) for the global population was 38% (33–44) and 28%(24–34) and for PBSC SCT patients 39%(33–46) and 32%(27–39) respectively. The 3-year probability of OS varied according to diagnosis (CLL: 62%, NHL:50%, CML:44%, MM:41%, MDS:37%, AML:26%, ALL:20%) and cGVHD (no:28%, yes:61%). The cumulative TRM incidence was 12% at 1 year and 13% at 3 years. A multivariate analysis was performed studying pre and post transplant factors for OS, EFS and GVHD:. Table 1 summarizes all variables showing a significant impact on OS and EFS. Furthermore, analyses showed the impact of one variable on AGVHD and cGVHD for PBSCT population: FBS with ATG 1day vs 2 days [HR:1.56(1.19–2.04) p=0.001, HR:1.50(1.14–1.97) p=0.003]. In conclusion, besides the influence of known factors on OS and EFS after RIC HSCT, this study pointed out, on a large series with a long-term follow-up, the major impact of disease status, acute and chronic GVHD and demonstrated the important role of ATG duration on GVHD incidence. Table 1: Multivariate analyses OS/EFS Variables OS (HR) p EFS (HR) p Conditionning :FBS ATG 1d vs 2 d Global 1.47 (1–2.2) 0,05 NS PBSC 1.6 (1.03–2.49) 0,04 NS FBS ATG 5d vs 2 d PBSC NS 1.13(1.04–1,24) < 0.01 PD vs CR Global 1.22 (1.1–1.32) < 0.01 1.15 (1.07–1.25) < 0.01 PBSC 1.2 (1.1–1,3) < 0.01 1.14 (1.05–1.24) < 0.01 Previous HSCT: yes vs no Global 1.27 (1.02–1,59) 0,04 1.25 (1.01–1.55) 0.04 AGVHD : Grade II vs 0-I PBSC 1.21 (1–1.47) 0,05 NS AGVHD : Grade III-IV vs 0-I Global 1,28 (1,14–1,43) < 0.01 1.12 (1–1.25) 0.04 PBSC 1.3 (1.14–1.47) < 0.01 1.13 (1–1.28) 0.05 cGVHD : yes vs no Global 0.2 (0.14–0.28) < 0.01 0.25 (0.19–0.35) < 0.01 PBSC 0.19 (0.13–0.28) < 0.01 0.25 (0.18–0.34) < 0.01" @default.
• W2584244377 created "2017-02-10" @default.
• W2584244377 creator A5008084507 @default.
• W2584244377 creator A5022161221 @default.
• W2584244377 creator A5029435774 @default.
• W2584244377 creator A5034473496 @default.
• W2584244377 creator A5035222674 @default.
• W2584244377 creator A5053452922 @default.
• W2584244377 creator A5072027146 @default.
• W2584244377 creator A5076734375 @default.
• W2584244377 creator A5087870886 @default.
• W2584244377 date "2005-11-16" @default.
• W2584244377 modified "2023-10-18" @default.
• W2584244377 title "Updated Analysis of Hematopoietic Stem Cell Transplantations after Reduced Intensity Conditioning Regimen (RIC HSCT) for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry." @default.
• W2584244377 doi "https://doi.org/10.1182/blood.v106.11.45.45" @default.
• W2584244377 hasPublicationYear "2005" @default.
• W2584244377 type Work @default.
• W2584244377 sameAs 2584244377 @default.
• W2584244377 citedByCount "2" @default.
• W2584244377 countsByYear W25842443772015 @default.
• W2584244377 crossrefType "journal-article" @default.
• W2584244377 hasAuthorship W2584244377A5008084507 @default.
• W2584244377 hasAuthorship W2584244377A5022161221 @default.
• W2584244377 hasAuthorship W2584244377A5029435774 @default.
• W2584244377 hasAuthorship W2584244377A5034473496 @default.
• W2584244377 hasAuthorship W2584244377A5035222674 @default.
• W2584244377 hasAuthorship W2584244377A5053452922 @default.
• W2584244377 hasAuthorship W2584244377A5072027146 @default.
• W2584244377 hasAuthorship W2584244377A5076734375 @default.
• W2584244377 hasAuthorship W2584244377A5087870886 @default.
• W2584244377 hasConcept C126322002 @default.
• W2584244377 hasConcept C141071460 @default.
• W2584244377 hasConcept C2776694085 @default.
• W2584244377 hasConcept C2776755627 @default.
• W2584244377 hasConcept C2777408962 @default.
• W2584244377 hasConcept C2779263901 @default.
• W2584244377 hasConcept C2780007613 @default.
• W2584244377 hasConcept C2780611847 @default.
• W2584244377 hasConcept C2781413609 @default.
• W2584244377 hasConcept C2908647359 @default.
• W2584244377 hasConcept C2911091166 @default.
• W2584244377 hasConcept C71924100 @default.
• W2584244377 hasConcept C90924648 @default.
• W2584244377 hasConcept C99454951 @default.
• W2584244377 hasConceptScore W2584244377C126322002 @default.
• W2584244377 hasConceptScore W2584244377C141071460 @default.
• W2584244377 hasConceptScore W2584244377C2776694085 @default.
• W2584244377 hasConceptScore W2584244377C2776755627 @default.
• W2584244377 hasConceptScore W2584244377C2777408962 @default.
• W2584244377 hasConceptScore W2584244377C2779263901 @default.
• W2584244377 hasConceptScore W2584244377C2780007613 @default.
• W2584244377 hasConceptScore W2584244377C2780611847 @default.
• W2584244377 hasConceptScore W2584244377C2781413609 @default.
• W2584244377 hasConceptScore W2584244377C2908647359 @default.
• W2584244377 hasConceptScore W2584244377C2911091166 @default.
• W2584244377 hasConceptScore W2584244377C71924100 @default.
• W2584244377 hasConceptScore W2584244377C90924648 @default.
• W2584244377 hasConceptScore W2584244377C99454951 @default.
• W2584244377 hasLocation W25842443771 @default.
• W2584244377 hasOpenAccess W2584244377 @default.
• W2584244377 hasPrimaryLocation W25842443771 @default.
• W2584244377 hasRelatedWork W1955322177 @default.
• W2584244377 hasRelatedWork W1984641455 @default.
• W2584244377 hasRelatedWork W2360634842 @default.
• W2584244377 hasRelatedWork W2405138071 @default.
• W2584244377 hasRelatedWork W2593968947 @default.
• W2584244377 hasRelatedWork W3002680405 @default.
• W2584244377 hasRelatedWork W3123349251 @default.
• W2584244377 hasRelatedWork W3137364747 @default.
• W2584244377 hasRelatedWork W3174720739 @default.
• W2584244377 hasRelatedWork W3213199609 @default.
• W2584244377 isParatext "false" @default.
• W2584244377 isRetracted "false" @default.
• W2584244377 magId "2584244377" @default.
• W2584244377 workType "article" @default.